|
1
|
Sporn MB, Dowsett SA, Mershon J and Bryant
HU: Role of raloxifene in breast cancer prevention in
postmenopausal women: Clinical evidence and potential mechanisms of
action. Clin Ther. 26:830–840. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jordan VC and Koerner S: Inhibition of
oestradiol binding to mouse uterine and vaginal oestrogen receptors
by triphenylethylenes. J Endocrinol. 64:193–194. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Croxtall JD, Emmas C, White JO, Choudhary
Q and Flower RJ: Tamoxifen inhibits growth of oestrogen
receptor-negative A549 cells. Biochem Pharmacol. 47:197–202. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Couldwell WT, Weiss MH, DeGiorgio CM,
Weiner LP, Hinton DR, Ehresmann GR, Conti PS, Apuzzo ML and Apuzzo
MLJ: Clinical and radiographic response in a minority of patients
with recurrent malignant gliomas treated with high-dose tamoxifen.
Neurosurgery. 32:485–489; discussion 489–490. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Del Prete SA, Maurer LH, O'Donnell J,
Forcier RJ and LeMarbre P: Combination chemotherapy with cisplatin,
carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Cancer Treat Rep. 68:1403–1405. 1984.PubMed/NCBI
|
|
6
|
Murphy LC and Sutherland RL: Differential
effects of tamoxifen and analogs with nonbasic side chains on cell
proliferation in vitro. Endocrinology. 116:1071–1078. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Plowman PN: Tamoxifen as adjuvant therapy
in breast cancer. Current status Drugs. 46:819–833. 1993.
|
|
8
|
Taurin S, Allen KM, Scandlyn MJ and
Rosengren RJ: Raloxifene reduces triple-negative breast cancer
tumor growth and decreases EGFR expression. Int J Oncol.
43:785–792. 2013.PubMed/NCBI
|
|
9
|
Mandlekar S and Kong ANT: Mechanisms of
tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stuart EC and Rosengren RJ: The
combination of raloxifene and epigallocatechin gallate suppresses
growth and induces apoptosis in MDA-MB-231 cells. Life Sci.
82:943–948. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stuart EC, Jarvis RM and Rosengren RJ: In
vitro mechanism of action for the cytotoxicity elicited by the
combination of EGCG and raloxifene in MDA-MB-231 cells. Oncol Rep.
24:779–785. 2010.PubMed/NCBI
|
|
12
|
Anzano MA, Peer CW, Smith JM, Mullen LT,
Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB and Sporn
MB: Chemoprevention of mammary carcinogenesis in the rat: Combined
use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst.
88:123–125. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Somers-Edgar TJ, Taurin S, Larsen L,
Chandramouli A, Nelson MA and Rosengren RJ: Mechanisms for the
activity of heterocyclic cyclohexanone curcumin derivatives in
estrogen receptor negative human breast cancer cell lines. Invest
New Drugs. 29:87–97. 2011. View Article : Google Scholar
|
|
14
|
Yadav B, Taurin S, Larsen L and Rosengren
RJ: RL66 a second-generation curcumin analog has potent in vivo and
in vitro anticancer activity in ER-negative breast cancer models.
Int J Oncol. 41:1723–1732. 2012.PubMed/NCBI
|
|
15
|
Yadav B, Taurin S, Larsen L and Rosengren
RJ: RL71, a second-generation curcumin analog, induces apoptosis
and downregulates Akt in ER-negative breast cancer cells. Int J
Oncol. 41:1119–1127. 2012.PubMed/NCBI
|
|
16
|
Vichai V and Kirtikara K: Sulforhodamine B
colorimetric assay for cytotoxicity screening. Nat Protoc.
1:1112–1116. 2006. View Article : Google Scholar
|
|
17
|
Lu Z and Xu S: ERK1/2 MAP kinases in cell
survival and apoptosis. IUBMB Life. 58:621–631. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jang K, Kim M, Seo HS and Shin I: PTEN
sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for
the blockade of cell proliferation. Oncol Rep. 24:787–793.
2010.PubMed/NCBI
|
|
19
|
Niepel M, Hafner M, Pace EA, Chung M, Chai
DH, Zhou L, Muhlich JL, Schoeberl B and Sorger PK: Analysis of
growth factor signaling in genetically diverse breast cancer lines.
BMC Biol. 12:202014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yadav B, Taurin S, Rosengren RJ,
Schumacher M, Diederich M, Somers-Edgar TJ and Larsen L: Synthesis
and cytotoxic potential of heterocyclic cyclohexanone analogues of
curcumin. Bioorg Med Chem. 18:6701–6707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stuart EC, Larsen L and Rosengren RJ:
Potential mechanisms for the synergistic cytotoxicity elicited by
4-hydroxytamoxifen and epigallocatechin gallate in MDA-MB-231
cells. Int J Oncol. 30:1407–1412. 2007.PubMed/NCBI
|
|
22
|
Wood CD, Thornton TM, Sabio G, Davis RA
and Rincon M: Nuclear localization of p38 MAPK in response to DNA
damage. Int J Biol Sci. 5:428–437. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zarubin T and Han J: Activation and
signaling of the p38 MAP kinase pathway. Cell Res. 15:11–18. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Catzavelos C, Bhattacharya N, Ung YC,
Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I,
Kapusta L, et al: Decreased levels of the cell-cycle inhibitor
p27Kip1 protein: Prognostic implications in primary breast cancer.
Nat Med. 3:227–230. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
deFazio A, Chiew YE, McEvoy M, Watts CK
and Sutherland RL: Antisense estrogen receptor RNA expression
increases epidermal growth factor receptor gene expression in
breast cancer cells. Cell Growth Differ. 8:903–911. 1997.PubMed/NCBI
|
|
26
|
Roos W, Fabbro D, Küng W, Costa SD and
Eppenberger U: Correlation between hormone dependency and the
regulation of epidermal growth factor receptor by tumor promoters
in human mammary carcinoma cells. Proc Natl Acad Sci USA.
83:991–995. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Biswas DK, Shi Q, Baily S, Strickland I,
Ghosh S, Pardee AB and Iglehart JD: NF-kappa B activation in human
breast cancer specimens and its role in cell proliferation and
apoptosis. Proc Natl Acad Sci USA. 101:10137–10142. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nielsen TO, Hsu FD, Jensen K, Cheang M,
Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler
L, et al: Immunohistochemical and clinical characterization of the
basal-like subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grandis JR and Sok JC: Signaling through
the epidermal growth factor receptor during the development of
malignancy. Pharmacol Ther. 102:37–46. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhuang S and Schnellmann RG: A
death-promoting role for extracellular signal-regulated kinase. J
Pharmacol Exp Ther. 319:991–997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung
Y, Komarov AP, Keyomarsi K, Yarden Y and Seger R: Taxol-induced
apoptosis depends on MAP kinase pathways (ERK and p38) and is
independent of p53. Oncogene. 20:147–155. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu J, Mao W, Ding B and Liang CS:
ERKs/p53 signal transduction pathway is involved in
doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am
J Physiol Heart Circ Physiol. 295:H1956–H1965. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
She QB, Bode AM, Ma WY, Chen NY and Dong
Z: Resveratrol-induced activation of p53 and apoptosis is mediated
by extracellular-signal-regulated protein kinases and p38 kinase.
Cancer Res. 61:1604–1610. 2001.PubMed/NCBI
|
|
35
|
Nguyen TT, Tran E, Nguyen TH, Do PT, Huynh
TH and Huynh H: The role of activated MEK-ERK pathway in
quercetin-induced growth inhibition and apoptosis in A549 lung
cancer cells. Carcinogenesis. 25:647–659. 2004. View Article : Google Scholar
|
|
36
|
Kolch W, Halasz M, Granovskaya M and
Kholodenko BN: The dynamic control of signal transduction networks
in cancer cells. Nat Rev Cancer. 15:515–527. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dillon RL, White DE and Muller WJ: The
phosphatidyl inositol 3-kinase signaling network: Implications for
human breast cancer. Oncogene. 26:1338–1345. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Korutla L, Cheung JY, Mendelsohn J and
Kumar R: Inhibition of ligand-induced activation of epidermal
growth factor receptor tyrosine phosphorylation by curcumin.
Carcinogenesis. 16:1741–1745. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Korutla L and Kumar R: Inhibitory effect
of curcumin on epidermal growth factor receptor kinase activity in
A431 cells. Biochim Biophys Acta. 1224:597–600. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yamamoto Y, Hoshino Y, Ito T, Nariai T,
Mohri T, Obana M, Hayata N, Uozumi Y, Maeda M, Fujio Y, et al:
Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via
p38-MAP kinase in cardiac myocytes. Cardiovasc Res. 79:89–96. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee SL, Chou CC, Chuang HC, Hsu EC, Chiu
PC, Kulp SK, Byrd JC and Chen CS: Functional role of mTORC2 versus
integrin-linked kinase in mediating Ser473-Akt phosphorylation in
PTEN-negative prostate and breast cancer cell lines. PLoS One.
8:e671492013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
O'Brien NA, Browne BC, Chow L, Wang Y,
Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N and Slamon
DJ: Activated phosphoinositide 3-kinase/AKT signaling confers
resistance to trastuzumab but not lapatinib. Mol Cancer Ther.
9:1489–1502. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Taurin S, Sandbo N, Qin Y, Browning D and
Dulin NO: Phosphorylation of beta-catenin by cyclic AMP-dependent
protein kinase. J Biol Chem. 281:9971–9976. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin L, Hutzen B, Ball S, Foust E, Sobo M,
Deangelis S, Pandit B, Friedman L, Li C, Li PK, et al: New curcumin
analogues exhibit enhanced growth-suppressive activity and inhibit
AKT and signal transducer and activator of transcription 3
phosphorylation in breast and prostate cancer cells. Cancer Sci.
100:1719–1727. 2009. View Article : Google Scholar : PubMed/NCBI
|
